NCT00705536View on ClinicalTrials.gov

Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

February 29, 2008

Study Completion Date

February 29, 2008

Conditions
Diabetes Mellitus
Interventions
DRUG

Humalog

DRUG

Humulin-R

DRUG

Recombinant human hyaluronidase PH20 (rHuPH20)

Trial Locations (1)

78229

Diabetes and Glandular Disease Research, Inc., San Antonio

Sponsors
All Listed Sponsors
lead

Halozyme Therapeutics

INDUSTRY

NCT00705536 - Pharmacokinetic (PK), Pharmacodynamic (PD), and Safety Study of Subcutaneously Administered Humalog® With and Without Recombinant Human Hyaluronidase (rHuPH20)and Humulin-R® With and Without rHuPH20 | Biotech Hunter | Biotech Hunter